FDA extends review of Brilinta

WILMINGTON, Del. The Food and Drug Administration has extended the amount of review time for an AstraZeneca drug, AstraZeneca said Wednesday.

The FDA extended the date of completion for its review from Thursday to Dec. 16 for the drug Brilinta (ticagrelor), a drug used to treat acute coronary syndromes.

The drug also is under review in nine other areas, including Canada, Brazil and the European Union.